#### **BIOMARIN PHARMACEUTICAL INC**

Form 4

January 14, 2014

# FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**SECURITIES** 

OMB Number:

3235-0287

Expires:

5. Relationship of Reporting Person(s) to

Issuer

January 31, 2005

0.5

Estimated average burden hours per

**OMB APPROVAL** 

response...

if no longer subject to Section 16. Form 4 or Form 5 obligations

may continue.

See Instruction

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

2. Issuer Name and Ticker or Trading

**BIOMARIN PHARMACEUTICAL** 

Symbol

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person \*

**BIENAIME JEAN JACQUES** 

			BIOMARIN PHARMACEUTICAL INC [BMRN]				(Check all applicable)				
(Last)  C/O BIOM PHARMAC DIGITAL I	ARIN CEUTICAL INC.,	(Month/ 01/10/	3. Date of Earliest Transaction (Month/Day/Year) 01/10/2014				X Director 10% Owner X Officer (give title Other (specify below)				
	(Street)	4. If Am	nendment, D	ate Origin	al		6. Individual or	Joint/Group F	iling(Check		
NOVATO,	CA 94949	Filed(M	onth/Day/Yea	ur)			Applicable Line) _X_ Form filed by Form filed by Person	y One Reporting More than One			
(City)	(State)	(Zip) Tal	ble I - Non-	Derivative	e Secu	rities Acc	quired, Disposed	of, or Benefic	ially Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr. 8)	4. Securi on(A) or D (Instr. 3,	ispose 4 and (A) or	d of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Common Stock	01/10/2014(1)	01/10/2014	M	5,000	A	\$ 12.99	55,740	I	Shares Held in Bienaime Family Trust (2)		
Common Stock	01/10/2014(1)	01/10/2014	S	5,000	D	\$ 70 (3)	50,740	I	Shares held by Bienaime Family Trust (2)		
Common Stock							10,000	I	Held in irrevocable		

### Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

	Ů Ů								
								trust for Guillaume Bienaime (4)	
					10,000	I		Held in irrevocable trust for Pierre Bienaime (4)	
					10,000	I		Held in irrevocable trust for Paul Bienaime (4)	
					10,000	I		Held in irrevocable trust for Marc Bienaime (4)	
					20,000	I		Held in irrevocable trust for Aurelie Mitsuki Bienaime and Anais Kimiko (4)	
rt on a sepa	rate line for each class	s of securities benefic	Persons informa required displays	as who respo ation contain ed to respond s a currently	ond to the co ned in this fo d unless the	orm ar e form	re not	SEC 1474 (9-02)	
						vned			
	(Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	Securities	6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
			Code V	(A) (D)	Date Exerc	นธุลทเค	Expiration Date	<sup>1</sup> Title	Amount or Number of Shares
r	onversion Exercise rice of erivative	Table II - Derivat (e.g., pu  3. Transaction Date (Month/Day/Year) Exercise rice of erivative	Table II - Derivative Securities Acquires, puts, calls, warrants, of the securities Acquires, puts, calls, warrants, of the securities Acquires, puts, calls, warrants, of the securities and the securities Acquires and the securities are securities and the securities and the securities and the securities and the securities are securities and the securities and t	Table II - Derivative Securities Acquired, Disponent (e.g., puts, calls, warrants, options, conversion (Month/Day/Year) Execution Date, if Transaction any Code (Month/Day/Year) (Instr. 8) erivative eccurity	art on a separate line for each class of securities beneficially owned directly or in Persons who respond information contain required to respond displays a currently number.  Table II - Derivative Securities Acquired, Disposed of, or Benefice. Securities Acquired, Disposed of, or Benefice. Securities Acquired, Disposed of, or Benefice. Securities Acquired (Month/Day/Year) Execution Date, if Transaction of Derivative any Code Securities (Month/Day/Year) (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	any Code Securities  3. Transaction Date (e.g., puts, calls, warrants, options, convertible securities)  3. Transaction Date 3A. Deemed (Month/Day/Year)  Exercise of erivative (Month/Day/Year)  (Instr. 8)  Acquired (A) or Disposed of (D)  (Instr. 3, 4, and 5)  Date Exercise	at on a separate line for each class of securities beneficially owned directly or indirectly.  Persons who respond to the collectic information contained in this form an required to respond unless the form displays a currently valid OMB control onversion (Month/Day/Year)  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)  3. Transaction Date 3A. Deemed (Month/Day/Year) Execution Date, if Transactionef Derivative Code Securities (Month/Day/Year) (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)  Date Exercisable	rt on a separate line for each class of securities beneficially owned directly or indirectly.  Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)  Exercise of (Month/Day/Year) Execution Date, if Transaction of Derivative (A) or Disposed of (D) (Instr. 3, 4, and 5)  Date Exercisable Expiration Date	Guillaume Bicnaime (4) Held in irrevocable trust for Pierre Bienaime (4) Held in irrevocable trust for Paul Bicnaime (4) Held in irrevocable trust for Paul Bicnaime (4) Held in irrevocable trust for Paul Bicnaime (4) Held in irrevocable trust for Aurelie Mitsuki Bienaime and Anais Kimiko (4)  Table II - Derivative Securities beneficially owned directly or indirectly.  Fersons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control unumber.  Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)  3. Transaction Date 3A. Deemed (e.g., puts, calls, warrants, options, convertible securities)  3. Transaction Date 3A. Deemed (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) Execution Date, if Transaction# Derivative Expiration Date (Month/Day/Year) (Month/Day/Year) (Instr. 3, 4, and 5)  Date Exercisable Expiration Date  Title

#### Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

Stock Option

(right to buy \$ 12.99  $01/10/2014\underline{^{(1)}}$  01/10/2014 M 5,000  $11/11/2006\underline{^{(5)}}$  05/10/2016 Common Stock

Common Stock)

## **Reporting Owners**

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

5,000

BIENAIME JEAN JACQUES C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO, CA 94949

X Chief Executive Officer

## **Signatures**

/s/ Laura Randall Woodhead,
Attorney-in-Fact
01/14/2014

\*\*Signature of Reporting Person Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to a Rule 10b5-1 trading plan executed on February 26, 2013.
- (2) The reporting person and his spouse act as trustees for the Bienaime Family Trust.
- (3) All shares sold at same price.
- (4) The reporting person's spouse is trustee of each child's trust.
- (5) Original option grant vests 6/48th on November 11, 2006, and 1/48th on the 11th day of every month thereafter
- (6) Reflects the number of stock options outstanding after the transaction from this specific stock option grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 3